. Author manuscript; available in PMC: 2020 Mar 2.

Published in final edited form as: Clin Gastroenterol Hepatol. 2018 Aug 8;17(5):864–868. doi: 10.1016/j.cgh.2018.07.008

Table 1.

Baseline Patient Characteristics, Comorbidities, Medications, and BE length

	All patients (n = 1883)	≥1 cm and <3 cm (n = 822)	≥3 cm (n = 1061)	P value
Age, y	57.3 ± 17.4	58.3 ± 14.3	56.6 ± 19.4	.035
Male	1572 (83.5)	690 (83.9)	882 (83.1)	.637
BMI, kg/m²	27.7 ± 5.4	28.4 ± 5.7	27.2 ± 5.1	<.001
Smoking	1057 (56.1)	490 (59.6)	567 (53.4)	.007
PPI	1821 (96)	794 (96)	1027 (96)	.84
ASA	600 (39.4)	334 (48.8)	498 (31.8)	<.001
Statin	581 (60.3%)	357 (65.4)	224 (53.6)	<.001
Hypertension	673 (64.3)	394 (67.5)	279 (60.3)	.015
Diabetes	361 (33.4)	214 (36.0)	147 (30.2)	.042
H2RA use	1323 (70.3)	525 (63.9)	798 (75.2)	<.001
BE length, cm	3.9 ± 3.0	1.5 ± 0.5	5.7 ± 2.8	<.001
Follow-up time, y	6.4 (3.8–8.4)	5.8 (3.1–8.2)	6.9 (4.1–8.6)	.069

NOTE. Values are mean ± SD, n (%), or median (interquartile range).

ASA, acetylsalicylic acid; BE, Barrett’s esophagus; BMI, body mass index; H2RA, histamine 2 receptor antagonist; PPI, proton pump inhibitor.